Debiopharm continues fight against antibiotic resistance


Debiopharm Group invests in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics

ABAC Therapeutics develops new targeted antibiotics for patients with severe infections. The investment by the Debiophram Group was made through the Debiopharm Innovation Fund, its strategic investment fund, illustrating the synergy between the group companies in the fight against the worrying emergence of antibiotic resistance.

Debiopharm International, the drug development company of the group, is developing targeted antibiotics that represent the future of treating bacterial infections.

Its pipeline is based on afabicin, the first selective antibiotic against Staphylococci, currently in advanced development for skin and bone infections, as well as two earlier stage projects against multidrug-resistant pathogens among the WHO and CDC priority targets.

ABAC's PasNas research platform makes it possible to identify new targeted molecules and its most developed programme targets Acinetobacter, whose resistant forms are at the origin of many infections that are very difficult to treat. The companies' research skills are complementary to Debiopharm's expertise in pharmaceutical development.

"We are delighted with our investment in ABAC. The main focus of Debiopharm Innovation Fund's investments is smart data, but we also invest in pharmaceutical and diagnostic companies that are strategically important to Debiopharm Group. Just like us, ABAC is tackling antibiotic resistance, " said Thierry Mauvernay, President of Debiopharm Group.

Sign up for your free email newsletter